Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘NASDAQ:DRNA’

BRIDGER MANAGEMENT

Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)

At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting......(read more)
Oleg Nodelman EcoR1 Capital

Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA)

Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (......(read more)
Roberto-Mignone1

Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA)

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers......(read more)
easiest countries to get oxycodone prescribed

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
pharmacist, worker, shelves, business, counter, glasses, attractive, medical, competence, chemist, adult, clinic, drugstore, selling, female, consultation, medicine, coat

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
adriaticfoto/Shutterstock.com

13G Filing: EcoR1 Capital and Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Oleg Nodelman’s EcoR1 Capital filed an amended 13D. You can check out EcoR1 Capital’s latest holdings......(read more)
pharmacist, worker, shelves, business, counter, glasses, attractive, medical, competence, chemist, adult, clinic, drugstore, selling, female, consultation, medicine, coat

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
10 Pharmacist Shortage Countries in Need of Pharmacists in 2017

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management......(read more)
10 Pharmacist Shortage Countries in Need of Pharmacists in 2017

13D Filing: Bain Capital Life Sciences Fund, L.P. and Dicerna Pharmaceuticals Inc (DRNA)

You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 5 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE......(read more)

13D Filing: Bain Capital Life Sciences Fund, L.p. and Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 12 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE......(read more)
Peter Kolchinsky

13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 9 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE......(read more)
10 Uncommon Genetic Mutations in Humans

Micro-Cap Biotech Focus: Dicerna Pharmaceuticals Inc (DRNA) Presents Its Exciting New Drug Platform GalXC

By Jutta Schulze Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a biopharmaceutical company that focuses on a technology called RNA interference (RNAi).......(read more)
Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

Do Hedge Funds Love Dicerna Pharmaceuticals Inc (DRNA)?

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors......(read more)
science, lab, researching, research, medical, team, scientist, group, chemistry, test, experiment, pharmaceutical, scrutiny, holds, practitioner, chemist, laboratory, clinic, teamwork,

Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore

As we already know from media reports and hedge fund investor letters, many hedge funds lost money in the third quarter, blaming macroeconomic conditions......(read more)
Peter Kolchinsky

RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech

The biotechnology industry is up by more than 50% over the last year, but these towering returns don’t come without great risk and volatility. However......(read more)
Entegris Inc (NASDAQ:ENTG)

Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves

In two new filings, Thomas E. Claugus‘ GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG). The investor revealed buying......(read more)
Peter Kolchinsky

Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside

Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million......(read more)
Dicerna Pharmaceuticals Inc

Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E. Flynn, and Bain Capital’s Brookside Capital......(read more)